Arbutus Biopharma (ABUS) Competitors $3.13 -0.01 (-0.32%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.16 +0.03 (+0.96%) As of 07/18/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. IBRX, GMTX, ARWR, APLS, NAMS, TWST, DNLI, KNSA, AGIO, and RXRXShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals ImmunityBio (NASDAQ:IBRX) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation. Does the media prefer IBRX or ABUS? In the previous week, ImmunityBio had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 1 mentions for ImmunityBio and 0 mentions for Arbutus Biopharma. ImmunityBio's average media sentiment score of 0.38 beat Arbutus Biopharma's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media. Company Overall Sentiment ImmunityBio Neutral Arbutus Biopharma Neutral Which has more risk and volatility, IBRX or ABUS? ImmunityBio has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Which has preferable valuation & earnings, IBRX or ABUS? Arbutus Biopharma has lower revenue, but higher earnings than ImmunityBio. Arbutus Biopharma is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M164.67-$413.56M-$0.58-4.74Arbutus Biopharma$6.17M97.16-$69.92M-$0.41-7.63 Is IBRX or ABUS more profitable? Arbutus Biopharma has a net margin of -1,196.64% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-1,310.30% N/A -121.88% Arbutus Biopharma -1,196.64%-75.51%-55.81% Do analysts recommend IBRX or ABUS? ImmunityBio currently has a consensus price target of $12.25, indicating a potential upside of 345.45%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 75.72%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImmunityBio is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of IBRX or ABUS? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 76.8% of ImmunityBio shares are held by company insiders. Comparatively, 20.3% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryImmunityBio beats Arbutus Biopharma on 10 of the 16 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$601.40M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-7.6319.7528.0119.82Price / Sales97.16300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book6.147.678.125.65Net Income-$69.92M-$55.28M$3.25B$257.91M7 Day Performance-1.26%4.85%1.68%3.38%1 Month Performance-9.80%11.70%7.30%11.11%1 Year Performance-15.18%3.69%32.89%18.99% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.1384 of 5 stars$3.13-0.3%$5.50+75.7%-15.2%$601.40M$6.17M-7.6390IBRXImmunityBio2.2825 of 5 stars$2.72flat$12.25+350.4%-54.0%$2.40B$31.22M-4.69590GMTXGemini TherapeuticsN/A$54.75+3.0%N/A+21.4%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.8394 of 5 stars$16.84+0.3%$43.71+159.6%-39.4%$2.33B$3.55M-12.03400News CoveragePositive NewsAnalyst DowngradeAPLSApellis Pharmaceuticals4.3257 of 5 stars$17.42-4.6%$39.79+128.4%-48.7%$2.19B$781.37M-9.73770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNAMSNewAmsterdam Pharma3.6029 of 5 stars$19.46-2.0%$42.89+120.4%+18.3%$2.18B$45.56M-10.354News CoverageAnalyst ForecastInsider TradeTWSTTwist Bioscience4.2169 of 5 stars$35.59-6.8%$50.40+41.6%-34.3%$2.13B$312.97M-10.95990News CoverageDNLIDenali Therapeutics4.5366 of 5 stars$14.25-3.0%$33.71+136.6%-35.7%$2.07B$330.53M-5.34430KNSAKiniksa Pharmaceuticals International3.3478 of 5 stars$27.95+0.3%$38.80+38.8%+37.1%$2.04B$481.17M-111.80220Positive NewsUpcoming EarningsInsider TradeAGIOAgios Pharmaceuticals4.4049 of 5 stars$35.21-2.4%$58.60+66.4%-16.1%$2.04B$36.50M3.13390RXRXRecursion Pharmaceuticals1.1305 of 5 stars$4.93-6.5%$7.00+42.0%-25.8%$2.00B$59.82M-2.79400Gap UpHigh Trading Volume Related Companies and Tools Related Companies IBRX Alternatives GMTX Alternatives ARWR Alternatives APLS Alternatives NAMS Alternatives TWST Alternatives DNLI Alternatives KNSA Alternatives AGIO Alternatives RXRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
